Walter Alarco
Research Subjects
Research Interests
Walter Alarco has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Romero
Servicio de Cardiología, Hospital Santo Tomas Ciudad de Panamá Panamá
4 shared publications - Eduardo Roque Perna
Federación Argentina de Cardiología
4 shared publications - Juan Esteban Gómez-Mesa
Departamento de Cardiología, Fundación Valle del Lili, Cali, Colombia
4 shared publications - Mario Speranza
Departamento de Cardiología Hospital Clínica Bíblica San José Costa Rica
4 shared publications - Andrea Valencia-Orozco
Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali 760032, Colombia
3 shared publications - Manuela Escalante
Facultad de Ciencias de la Salud, Universidad ICESI, Cali, Valle del Cauca, Colombia
3 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (11)
Pulmonary embolism or a fatal mimic? Wall-eclipsing sign and metastatic tissue diagnosis in pulmonary artery intimal sarcoma: a case report
Background: Pulmonary artery intimal sarcoma is a rare, aggressive malignancy that may mimic chronic pulmonary infection and chronic thromboembolic disease. This case highlights the need to reconsider a thromboembolic diagnosis when pulmonary arterial obstruction persists despite anticoagulation and is associated with the wall-eclipsing sign and progressive right ventricular failure. Case summary: A 50-year-old woman presented with 3 months of intermittent haemoptysis and progressive dyspnoea. Initial evaluation suggested chronic infectious lung disease; however, transthoracic echocardiography identified a mass involving the main pulmonary artery. Computed tomography pulmonary angiography was initially interpreted as chronic pulmonary thromboembolism, and anticoagulation was initiated. Shortly thereafter, life-threatening haemoptysis required high-flow nasal oxygen therapy, transfusion of four units of packed red blood cells, and vasopressor support. Follow-up imaging showed persistent pulmonary arterial obstruction with progressive right ventricular failure. Repeat computed tomography pulmonary angiography demonstrated an infiltrative pulmonary artery mass with intrinsic enhancement, left atrial extension, and the wall-eclipsing sign. Breast nodules and axillary lymphadenopathy prompted biopsy of an accessible breast lesion, which revealed a high-grade spindle-cell neoplasm with CD31 and ERG expression, supporting angiosarcomatous differentiation, together with nuclear MDM2 immunoreactivity. Fluorescence in situ hybridization demonstrated MDM2 gene amplification in the breast biopsy, supporting the integrated diagnosis of pulmonary artery intimal sarcoma with angiosarcomatous differentiation and breast metastasis. Discussion: This case highlights the need to reconsider chronic thromboembolic disease when pulmonary arterial obstruction persists despite anticoagulation, particularly in the presence of the wall-eclipsing sign. Metastatic tissue sampling may establish the diagnosis while avoiding high-risk intravascular biopsy.
- 8 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (11)
Open AccessPulmonary embolism or a fatal mimic? Wall-eclipsing sign and metastatic tissue diagnosis in pulmonary artery intimal sarcoma: a case report
Background: Pulmonary artery intimal sarcoma is a rare, aggressive malignancy that may mimic chronic pulmonary infection and chronic thromboembolic disease. This case highlights the need to reconsider a thromboembolic diagnosis when pulmonary arterial obstruction persists despite anticoagulation and is associated with the wall-eclipsing sign and progressive right ventricular failure. Case summary: A 50-year-old woman presented with 3 months of intermittent haemoptysis and progressive dyspnoea. Initial evaluation suggested chronic infectious lung disease; however, transthoracic echocardiography identified a mass involving the main pulmonary artery. Computed tomography pulmonary angiography was initially interpreted as chronic pulmonary thromboembolism, and anticoagulation was initiated. Shortly thereafter, life-threatening haemoptysis required high-flow nasal oxygen therapy, transfusion of four units of packed red blood cells, and vasopressor support. Follow-up imaging showed persistent pulmonary arterial obstruction with progressive right ventricular failure. Repeat computed tomography pulmonary angiography demonstrated an infiltrative pulmonary artery mass with intrinsic enhancement, left atrial extension, and the wall-eclipsing sign. Breast nodules and axillary lymphadenopathy prompted biopsy of an accessible breast lesion, which revealed a high-grade spindle-cell neoplasm with CD31 and ERG expression, supporting angiosarcomatous differentiation, together with nuclear MDM2 immunoreactivity. Fluorescence in situ hybridization demonstrated MDM2 gene amplification in the breast biopsy, supporting the integrated diagnosis of pulmonary artery intimal sarcoma with angiosarcomatous differentiation and breast metastasis. Discussion: This case highlights the need to reconsider chronic thromboembolic disease when pulmonary arterial obstruction persists despite anticoagulation, particularly in the presence of the wall-eclipsing sign. Metastatic tissue sampling may establish the diagnosis while avoiding high-risk intravascular biopsy.
- Open Access
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (9) , e046820
Comorbidity Clusters in Acute Heart Failure: Insights From the AMERICCAASS Registry
Background: Acute heart failure (HF) frequently coexists with multimorbidity. Comorbidity clusters have been associated with distinct clinical outcomes, but data from the Americas remain limited. We aimed to identify comorbidity clusters in patients with acute HF and assess their association with in‐hospital outcomes. Methods: This cohort study applied latent class analysis to patients from the AMERICCAASS Registry (Registro Americano de Insuficiencia Cardiaca Ambulatoria o Agudamente descompensada). Adjusted Poisson regression assessed in‐hospital mortality and intensive care unit (ICU) admission, and multivariable analysis identified independent predictors of ICU admission. Results: Among 1638 patients, 60.6% were men and the median age was 67.2 years. Hypertension (69.4%), smoking (40.3%), and coronary artery disease (33.8%) were common comorbidities. Cluster 1 (Young, n=828) included the youngest patients (median age 63.2 years) with the fewest comorbidities. Cluster 2 (Cardio‐Kidney‐Metabolic, n=512) represented the oldest group (median age 71.8 years) with the highest median body mass index (27.7 kg/m 2 ), the greatest proportion of HF with mildly reduced or preserved ejection fraction (44.7%), and a high comorbidity burden. Cluster 3 (“Ischemic,” n=298) was characterized by older patients (median age 70.2 years) with an exceptionally high prevalence of coronary artery disease (96.3%) and the greatest proportion of HF with reduced ejection fraction (61.4%). ICU admission risk was higher in Cluster 2 (adjusted risk ratio [aRR], 1.15 [95% CI, 1.03–1.27]; P =0.009) and Cluster 3 (aRR, 1.25 [95% CI, 1.12–1.39]; P <0.001), compared with Cluster 1. Severe valvular insufficiency, peripheral artery disease, dyslipidemia, cancer, acute coronary syndrome, anemia, and cardiogenic shock were associated with higher ICU admission risk. Conclusions: Patients with acute HF in the Americas exhibit distinct comorbidity patterns associated with different clinical profiles and ICU admission rates, which may inform risk stratification and management strategies. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05295641.
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (9) , e046820
Open AccessComorbidity Clusters in Acute Heart Failure: Insights From the AMERICCAASS Registry
Background: Acute heart failure (HF) frequently coexists with multimorbidity. Comorbidity clusters have been associated with distinct clinical outcomes, but data from the Americas remain limited. We aimed to identify comorbidity clusters in patients with acute HF and assess their association with in‐hospital outcomes. Methods: This cohort study applied latent class analysis to patients from the AMERICCAASS Registry (Registro Americano de Insuficiencia Cardiaca Ambulatoria o Agudamente descompensada). Adjusted Poisson regression assessed in‐hospital mortality and intensive care unit (ICU) admission, and multivariable analysis identified independent predictors of ICU admission. Results: Among 1638 patients, 60.6% were men and the median age was 67.2 years. Hypertension (69.4%), smoking (40.3%), and coronary artery disease (33.8%) were common comorbidities. Cluster 1 (Young, n=828) included the youngest patients (median age 63.2 years) with the fewest comorbidities. Cluster 2 (Cardio‐Kidney‐Metabolic, n=512) represented the oldest group (median age 71.8 years) with the highest median body mass index (27.7 kg/m 2 ), the greatest proportion of HF with mildly reduced or preserved ejection fraction (44.7%), and a high comorbidity burden. Cluster 3 (“Ischemic,” n=298) was characterized by older patients (median age 70.2 years) with an exceptionally high prevalence of coronary artery disease (96.3%) and the greatest proportion of HF with reduced ejection fraction (61.4%). ICU admission risk was higher in Cluster 2 (adjusted risk ratio [aRR], 1.15 [95% CI, 1.03–1.27]; P =0.009) and Cluster 3 (aRR, 1.25 [95% CI, 1.12–1.39]; P <0.001), compared with Cluster 1. Severe valvular insufficiency, peripheral artery disease, dyslipidemia, cancer, acute coronary syndrome, anemia, and cardiogenic shock were associated with higher ICU admission risk. Conclusions: Patients with acute HF in the Americas exhibit distinct comorbidity patterns associated with different clinical profiles and ICU admission rates, which may inform risk stratification and management strategies. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05295641.
- Open Access
- 30 June 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (7) , 205
Association of Abnormal Cardiac Biomarkers and Cardiovascular Complications, with Mortality in Patients with SARS-CoV-2 Infection in Latin America
Background: The COVID-19 pandemic has highlighted a correlation between cardiac complications and elevated cardiac biomarkers, which are linked to poorer clinical outcomes. Objective: This study aims to determine the clinical impact of cardiac biomarkers in COVID-19 patients in Latin America. Subjects and methods: The CARDIO COVID 19-20 Registry is a multicenter observational study across 44 hospitals in Latin America and the Caribbean. It included hospitalized COVID-19 patients (n = 476) who underwent troponin, natriuretic peptide, and D-dimer tests. Patients were grouped based on the number of positive biomarkers. Results: Among the 476 patients tested, 139 had one positive biomarker (Group C), 190 had two (Group B), 118 had three (Group A), and 29 had none (Group D). A directly proportional relationship was observed between the number of positive biomarkers and the incidence of decompensated heart failure. Similarly, there was a proportional relationship between the number of positive biomarkers and increased mortality. In Group B, patients with elevated troponin and natriuretic peptide and those with elevated troponin and D-dimer had 1.4 and 1.5 times higher mortality, respectively, than those with elevated natriuretic peptide and D-dimer. Conclusions: In Latin American COVID-19 patients, a higher number of positive cardiac biomarkers is associated with increased cardiovascular complications and mortality. These findings suggest that cardiac biomarkers should be utilized to guide acute-phase treatment strategies.
- 30 June 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (7) , 205
Open AccessAssociation of Abnormal Cardiac Biomarkers and Cardiovascular Complications, with Mortality in Patients with SARS-CoV-2 Infection in Latin America
Background: The COVID-19 pandemic has highlighted a correlation between cardiac complications and elevated cardiac biomarkers, which are linked to poorer clinical outcomes. Objective: This study aims to determine the clinical impact of cardiac biomarkers in COVID-19 patients in Latin America. Subjects and methods: The CARDIO COVID 19-20 Registry is a multicenter observational study across 44 hospitals in Latin America and the Caribbean. It included hospitalized COVID-19 patients (n = 476) who underwent troponin, natriuretic peptide, and D-dimer tests. Patients were grouped based on the number of positive biomarkers. Results: Among the 476 patients tested, 139 had one positive biomarker (Group C), 190 had two (Group B), 118 had three (Group A), and 29 had none (Group D). A directly proportional relationship was observed between the number of positive biomarkers and the incidence of decompensated heart failure. Similarly, there was a proportional relationship between the number of positive biomarkers and increased mortality. In Group B, patients with elevated troponin and natriuretic peptide and those with elevated troponin and D-dimer had 1.4 and 1.5 times higher mortality, respectively, than those with elevated natriuretic peptide and D-dimer. Conclusions: In Latin American COVID-19 patients, a higher number of positive cardiac biomarkers is associated with increased cardiovascular complications and mortality. These findings suggest that cardiac biomarkers should be utilized to guide acute-phase treatment strategies.
- Open Access
- 23 January 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (2) , 34
Cardiovascular Complications in Patients with Heart Failure and COVID-19: CARDIO COVID 19-20 Registry
Since early 2020, different studies have shown an increased prevalence of COVID-19 and poorer prognosis in older adults with cardiovascular comorbidities. This study aimed to assess the impact of heart failure (HF) on cardiovascular complications, intensive care unit (ICU) admissions, and in-hospital mortality in patients hospitalized with COVID-19. The CARDIO COVID 19-20 registry includes 3260 hospitalized patients with a COVID-19 serological diagnosis between May 2020 and June 2021 from Latin American countries. A history of HF was identified in 182 patients (5.6%). In patients with and without previous HF, the incidence of supraventricular arrhythmia was 16.5% vs. 6.3%, respectively (p = 0.001), and that of acute coronary syndrome was 7.1% vs. 2.7%, respectively (p = 0.001). Patients with a history of HF had higher rates of ICU admission (61.5% vs. 53.1%, respectively; p = 0.031) and in-hospital mortality (41.8% vs. 24.5%, respectively; p = 0.001) than patients without HF. Cardiovascular mortality at discharge (42.1% vs. 18.5%, respectively; p < 0.001) and at 30 days post-discharge (66.7% vs. 18.0%, respectively) was higher for patients with a history of HF than for patients without HF. In patients hospitalized with COVID-19, previous history of HF was associated with a more severe cardiovascular profile, with increased risk of cardiovascular complications, and poor in-hospital and 30-day outcomes.
- 23 January 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (2) , 34
Open AccessCardiovascular Complications in Patients with Heart Failure and COVID-19: CARDIO COVID 19-20 Registry
Since early 2020, different studies have shown an increased prevalence of COVID-19 and poorer prognosis in older adults with cardiovascular comorbidities. This study aimed to assess the impact of heart failure (HF) on cardiovascular complications, intensive care unit (ICU) admissions, and in-hospital mortality in patients hospitalized with COVID-19. The CARDIO COVID 19-20 registry includes 3260 hospitalized patients with a COVID-19 serological diagnosis between May 2020 and June 2021 from Latin American countries. A history of HF was identified in 182 patients (5.6%). In patients with and without previous HF, the incidence of supraventricular arrhythmia was 16.5% vs. 6.3%, respectively (p = 0.001), and that of acute coronary syndrome was 7.1% vs. 2.7%, respectively (p = 0.001). Patients with a history of HF had higher rates of ICU admission (61.5% vs. 53.1%, respectively; p = 0.031) and in-hospital mortality (41.8% vs. 24.5%, respectively; p = 0.001) than patients without HF. Cardiovascular mortality at discharge (42.1% vs. 18.5%, respectively; p < 0.001) and at 30 days post-discharge (66.7% vs. 18.0%, respectively) was higher for patients with a history of HF than for patients without HF. In patients hospitalized with COVID-19, previous history of HF was associated with a more severe cardiovascular profile, with increased risk of cardiovascular complications, and poor in-hospital and 30-day outcomes.
- Open Access
- 23 January 2023
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 18 (1) , 60
Latin-American Registry of Cardiovascular Disease and COVID-19: Final Results
Background: Socioeconomic factors contribute to a more severe impact of COVID-19 in Latin American and Caribbean (LA&C) countries than in developed countries. Patients with a severe or critical illness can develop respiratory and cardiovascular complications. Objective: To describe a LA&C population with COVID-19 to provide information related to this disease, in-hospital cardiovascular complications, and in-hospital mortality. Methods: The CARDIO COVID-19–20 Registry is an observational, multicenter, prospective, and hospital-based registry of patients with confirmed COVID-19 infection that required in-hospital treatment in LA&C. Enrollment of patients started on May 01, 2020, and ended on June 30, 2021. Results: The CARDIO COVID-19–20 Registry included 3260 patients from 44 institutions of 14 LA&C countries. 63.2% patients were male and median age was 61.0 years old. Most common comorbidities were overweight/obesity (49.7%), hypertension (49.0%), and diabetes mellitus (26.7%). Most frequent cardiovascular complications during hospitalization or reported at discharge were cardiac arrhythmia (9.1%), decompensated heart failure (8.5%), and pulmonary embolism (3.9%). The number of patients admitted to the Intensive Care Unit (ICU) was 1745 (53.5%), and median length of their stay at the ICU was 10.0 days. Support required in ICU included invasive mechanical ventilation (34.2%), vasopressors (27.6%), inotropics (10.3%), and vasodilators (3.7%). Rehospitalization after 30-day post discharge was 7.3%. In-hospital mortality and 30-day post discharge were 25.5% and 2.6%, respectively. Conclusions: According to our findings, more than half of the LA&C population with COVID-19 assessed required management in ICU, with higher requirement of invasive mechanical ventilation and vasoactive support, resulting in a high in-hospital mortality and a considerable high 30-day post discharge rehospitalization and mortality.
- 23 January 2023
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 18 (1) , 60
Open AccessLatin-American Registry of Cardiovascular Disease and COVID-19: Final Results
Background: Socioeconomic factors contribute to a more severe impact of COVID-19 in Latin American and Caribbean (LA&C) countries than in developed countries. Patients with a severe or critical illness can develop respiratory and cardiovascular complications. Objective: To describe a LA&C population with COVID-19 to provide information related to this disease, in-hospital cardiovascular complications, and in-hospital mortality. Methods: The CARDIO COVID-19–20 Registry is an observational, multicenter, prospective, and hospital-based registry of patients with confirmed COVID-19 infection that required in-hospital treatment in LA&C. Enrollment of patients started on May 01, 2020, and ended on June 30, 2021. Results: The CARDIO COVID-19–20 Registry included 3260 patients from 44 institutions of 14 LA&C countries. 63.2% patients were male and median age was 61.0 years old. Most common comorbidities were overweight/obesity (49.7%), hypertension (49.0%), and diabetes mellitus (26.7%). Most frequent cardiovascular complications during hospitalization or reported at discharge were cardiac arrhythmia (9.1%), decompensated heart failure (8.5%), and pulmonary embolism (3.9%). The number of patients admitted to the Intensive Care Unit (ICU) was 1745 (53.5%), and median length of their stay at the ICU was 10.0 days. Support required in ICU included invasive mechanical ventilation (34.2%), vasopressors (27.6%), inotropics (10.3%), and vasodilators (3.7%). Rehospitalization after 30-day post discharge was 7.3%. In-hospital mortality and 30-day post discharge were 25.5% and 2.6%, respectively. Conclusions: According to our findings, more than half of the LA&C population with COVID-19 assessed required management in ICU, with higher requirement of invasive mechanical ventilation and vasoactive support, resulting in a high in-hospital mortality and a considerable high 30-day post discharge rehospitalization and mortality.
- Open Access
- 27 December 2021
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 2 (4) , 233-239
Características epidemiológicas de receptores de trasplante cardiaco en el Perú, 2010-2020
Objetivo. Evaluar las características epidemiológicas, clínicas, quirúrgicas, patológicas y desenlaces en el seguimiento de los pacientes receptores de trasplante cardiaco en el Instituto Nacional Cardiovascular durante 2010-2020. Materiales y métodos. Estudio retrospectivo descriptivo de pacientes sometidos a trasplante cardiaco en un centro de referencia nacional, se describen las características clínicas, quirúrgicas, de laboratorio, de patología y la supervivencia de los pacientes hasta los 10 años de seguimiento. Resultados. Ochenta y seis pacientes fueron trasplantados en 10 años, la mediana de edad fue de 41 años (RIQ 28-56), con predominancia de varones (66,3%). Las tres primeras causas de indicación de trasplante cardiaco fueron: cardiomiopatía dilatada (48,9%), cardiopatía isquémica (17,4%) y miocarditis (6,9%). El tiempo de isquemia total fue de 160 min (RIQ 129,7-233,5). La sobrevida al año, cinco y diez años fue de 84,8%, 73,6% y 65,7%, respectivamente. La principal causa de muerte fue la infecciosa (39,1%) y de origen desconocido (26%). Conclusiones. La principal etiología de la insuficiencia cardiaca en el receptor de trasplante cardiaco en el Perú, en los últimos años, fue la cardiomiopatía dilatada no isquémica. Se observa que la tasa de sobrevida fue similar a la de registros internacionales; sin embargo, la tasa de mortalidad de causa infecciosa y muerte de origen desconocido es alta, lo cual plantea un desafío en el manejo de los pacientes postrasplante.
- 27 December 2021
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 2 (4) , 233-239
Open AccessCaracterísticas epidemiológicas de receptores de trasplante cardiaco en el Perú, 2010-2020
Objetivo. Evaluar las características epidemiológicas, clínicas, quirúrgicas, patológicas y desenlaces en el seguimiento de los pacientes receptores de trasplante cardiaco en el Instituto Nacional Cardiovascular durante 2010-2020. Materiales y métodos. Estudio retrospectivo descriptivo de pacientes sometidos a trasplante cardiaco en un centro de referencia nacional, se describen las características clínicas, quirúrgicas, de laboratorio, de patología y la supervivencia de los pacientes hasta los 10 años de seguimiento. Resultados. Ochenta y seis pacientes fueron trasplantados en 10 años, la mediana de edad fue de 41 años (RIQ 28-56), con predominancia de varones (66,3%). Las tres primeras causas de indicación de trasplante cardiaco fueron: cardiomiopatía dilatada (48,9%), cardiopatía isquémica (17,4%) y miocarditis (6,9%). El tiempo de isquemia total fue de 160 min (RIQ 129,7-233,5). La sobrevida al año, cinco y diez años fue de 84,8%, 73,6% y 65,7%, respectivamente. La principal causa de muerte fue la infecciosa (39,1%) y de origen desconocido (26%). Conclusiones. La principal etiología de la insuficiencia cardiaca en el receptor de trasplante cardiaco en el Perú, en los últimos años, fue la cardiomiopatía dilatada no isquémica. Se observa que la tasa de sobrevida fue similar a la de registros internacionales; sin embargo, la tasa de mortalidad de causa infecciosa y muerte de origen desconocido es alta, lo cual plantea un desafío en el manejo de los pacientes postrasplante.
- Open Access
- 18 June 2021
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 2 (2) , 141-146
Taquicardia atrial focal incesante como causa de cardiomiopatía. A propósito de un caso
Focal atrial tachycardia is a rare type of supraventricular tachyarrhythmia, generally present in young people, and is a rare cause of tachycardiomyopathy (10%). We present a clinical case of tachycardiomyopathy in a 30-year-old man, without comorbidities, who was diagnosed with incessant focal atrial tachycardia, refractory to medical therapy, and electrical cardioversion. Succesful endocardial ablation was performed, and in outpatient follow-up at 6 months, he showed a recovery of the left ventricular ejection fraction and reduction of the left chambers to normal ranges, with progressive decrease of dyspnea.
- 18 June 2021
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 2 (2) , 141-146
Open AccessTaquicardia atrial focal incesante como causa de cardiomiopatía. A propósito de un caso
Focal atrial tachycardia is a rare type of supraventricular tachyarrhythmia, generally present in young people, and is a rare cause of tachycardiomyopathy (10%). We present a clinical case of tachycardiomyopathy in a 30-year-old man, without comorbidities, who was diagnosed with incessant focal atrial tachycardia, refractory to medical therapy, and electrical cardioversion. Succesful endocardial ablation was performed, and in outpatient follow-up at 6 months, he showed a recovery of the left ventricular ejection fraction and reduction of the left chambers to normal ranges, with progressive decrease of dyspnea.
- Open Access
- 30 March 2020
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 1 (1) , 6-14
Diabetes e Insuficiencia Cardíaca
Diabetes Mellitus (DM) is a chronic non-communicable cardio-metabolic disease that causes macro-vascular complications such as atherosclerosis, coronary disease and heart failure (HF). There is a bidi- rectional relationship between HF and DM, HF being the second most frequent initial cardiovascular event in patients with diabetes. It may even be the first cardiovascular complication, before acute my- ocardial infarction.DM can lead to HF through mechanisms mediated by atherosclerosis and non mediated by it. In the first case, cholesterol is deposited in coronary arteries, favored by the presence of other risk factors. In the second case, the myocardium is directly affected leading to structural and functional changes through non-atherogenic mechanisms (called Diabetic Cardiomyopathy).The treatment of HF with reduced ejection fraction in the diabetic patient does not differ from that of the non-diabetic population, the triple neurohumoral block must be achieved. In the case of patients with HF with ejection fraction preserved to date, we do not have specific therapy to reduce cardiovas- cular morbidity and mortality. In the diabetes treatment of the patient with HF, sodium-glucose type 2 cotransporter inhibitors (SGLT2i) clearly stand out. In addition to their glucosuric and natriuretic effect, they have pleiotropic effects that produce metabolic, hemodynamic and cellular viability effects preventing apoptosis and cell death. Finally, the clinical benefits of SGLT2 inhibitors in HF go beyond glycemic control, as demon- strated by the DAPA-HF study; initiating a new era in the treatment of patients with HF with reduced ejection fraction.
- 30 March 2020
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 1 (1) , 6-14
Open AccessDiabetes e Insuficiencia Cardíaca
Diabetes Mellitus (DM) is a chronic non-communicable cardio-metabolic disease that causes macro-vascular complications such as atherosclerosis, coronary disease and heart failure (HF). There is a bidi- rectional relationship between HF and DM, HF being the second most frequent initial cardiovascular event in patients with diabetes. It may even be the first cardiovascular complication, before acute my- ocardial infarction.DM can lead to HF through mechanisms mediated by atherosclerosis and non mediated by it. In the first case, cholesterol is deposited in coronary arteries, favored by the presence of other risk factors. In the second case, the myocardium is directly affected leading to structural and functional changes through non-atherogenic mechanisms (called Diabetic Cardiomyopathy).The treatment of HF with reduced ejection fraction in the diabetic patient does not differ from that of the non-diabetic population, the triple neurohumoral block must be achieved. In the case of patients with HF with ejection fraction preserved to date, we do not have specific therapy to reduce cardiovas- cular morbidity and mortality. In the diabetes treatment of the patient with HF, sodium-glucose type 2 cotransporter inhibitors (SGLT2i) clearly stand out. In addition to their glucosuric and natriuretic effect, they have pleiotropic effects that produce metabolic, hemodynamic and cellular viability effects preventing apoptosis and cell death. Finally, the clinical benefits of SGLT2 inhibitors in HF go beyond glycemic control, as demon- strated by the DAPA-HF study; initiating a new era in the treatment of patients with HF with reduced ejection fraction.